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Although the combination of immune checkpoint blockades with high dose of radiation
has indicated the potential of co-stimulatory effects, consistent clinical outcome has been
yet to be demonstrated. Bulky tumors present challenges for radiation treatment to
achieve high rate of tumor control due to large tumor sizes and normal tissue toxicities. As
an alternative, spatially fractionated radiotherapy (SFRT) technique has been applied, in
the forms of GRID or LATTICE radiation therapy (LRT), to safely treat bulky tumors. When
used alone in a single or a few fractions, GRID or LRT can be best classified as palliative or
tumor de-bulking treatments. Since only a small fraction of the tumor volume receive high
dose in a SFRT treatment, even with the anticipated bystander effects, total tumor
eradications are rare. Backed by the evidence of immune activation of high dose
radiation, it is logical to postulate that the combination of High-Dose LATTICE radiation
therapy (HDLRT) with immune checkpoint blockade would be effective and could
subsequently lead to improved local tumor control without added toxicities, through
augmenting the effects of radiation in-situ vaccine and T-cell priming. We herein present a
case of non-small cell lung cancer (NSCLC) with multiple metastases. The patient received
various types of palliative radiation treatments with combined chemotherapies and
immunotherapies to multiple lesions. One of the metastatic lesions measuring 63.2 cc
was treated with HDLRT combined with anti-PD1 immunotherapy. The metastatic mass
regressed 77.84% over one month after the treatment, and had a complete local
response (CR) five months after the treatment. No treatment-related side effects were
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observed during the follow-up exams. None of the other lesions receiving palliative
treatments achieved CR. The dramatic differential outcome of this case lends support
to the aforementioned postulate and prompts for further systemic clinical studies.
Keywords: lattice radiotherapy, high-dose LATTICE radiation therapy, immunotherapy, non-small cell lung cancer,
bulky tumor, spatially fractionated radiotherapy
INTRODUCTION
Lung cancer is the most commonly diagnosed cancer (11.6% of
the total cases) and the leading cause of cancer death (18.4% of
the total cancer deaths) based on the latest global cancer statistics
(1). Non-small cell lung cancer (NSCLC) accounts for about 85%
of all lung cancers, with approximately 40% of newly diagnosed
NSCLC patients presented with stage IV disease (2, 3).
Radiotherapy plays an important role in the definitive,
preoperative and postoperative management of early stage and
in the palliative treatment of advanced staged NSCLC. The use of
radiation as a local ablative therapy is now recommended in the
European Society for Medical Oncology (ESMO) guidelines for
patients with stage IV disease who subsequently develop
oligometastatic progression (4).
High ablative doses of local radiation therapy (RT), often
referred to as stereotactic radiosurgery (SRS) or stereotactic body
radiotherapy (SBRT) is usually applied to tumors with limited
size (5). The application of SRS or SBRT in bulky tumors is often
considered challenging due to the difficulties in controlling
toxicities of the surrounding normal/critical organs. Spatially
fractionated radiotherapy (SFRT) with GRID, proposed in 1909
and further developed since early 1950s, has been safely utilized
for the treatment of bulky and advanced tumors with
impressively accumulated clinical data (6–8). In recent years,
the 2D GRID technique was extended to a 3D configuration,
known as LATTICE radiotherapy (LRT) (9, 10). The safety and
clinical efficacy of LRT has been reported in various voluminous
tumors (11–15).
Based on the results of radiobiological studies, the possible
mechanisms behind the effectiveness of SFRT have been
attributed to certain bystander effects and abscopal effects,
such as the radiation-mediated anti-tumor immunity (16–23)
or perfusion modulation (10, 24). The key characteristics of
SFRT in either GRID or LRT configurations is the Peak-Valley
dose distribution, where high dose of radiation is delivered to
the peaks or vertices, leaving relatively lower dose in the valleys
(between the peaks or vertices) (9–15). In the context of
immune modulation, as long as the peak dose is sufficiently
high, although only partial volume of the tumor receives that
high dose, the induced anti-tumor immunity can be expected
and would subsequently contribute to the enhanced tumor
control (25–30). As radiation-mediated immune activation
follows the pathway of T-cell priming through antigen
presentation, for immunogenic tumors, combining immune
checkpoint blockades with high dose of radiation is a logical
strategy and has been extensively studied with encouraging
results (30–37). The recent studies also showed that
combined ablative dose with low dose of radiation could lead
to the reprograming of the immunosuppressive tumor
microenvironment (TME) to become more immunogenic
and synergistically augment the anti-tumor response (38).
This is an important insight as SFRT intrinsically combines
high and low dose in its Peak-Valley dose distribution.
All these have suggested that HDLRT, when combined with
checkpoint blockade immunotherapy could result in improved
tumor control.
In the following case report, a patient with multiple metastatic
lesions from a primary NSCLC received various regimens of
palliative treatments, including conformal radiotherapy (CRT),
intensity-modulated radiotherapy (IMRT), SBRT, LRT,
chemotherapy, and immunotherapy. Remarkably, only one
lesion treated with high-dose LRT (HDLRT) and anti-PD1
therapy achieved complete local response (CR).
CASE PRESENTATION
A 33-year-old female patient initially presented with a lung mass
in the right lower lobe, accompanied by cough for one month.
She underwent video-assisted thoracoscopic right lower
lobectomy and systemic mediastinal lymph node dissection as
curative intent resection on May 10, 2017. The surgical
histopathological report demonstrated diagnosis of invasive
adenocarcinoma in the lower lobe of the right lung. The lung
mass measured 7, 4.5, and 3.2 cm in the greatest dimensions.
Post-surgical staging was T3N2M0. Postoperatively, she received
two cycles of adjuvant chemotherapy of PP regimen (pemetrexed
disodium 0.8 g dl + cisplatin 0.4g dl) from June to August 2017.
In September 2017, the patient developed metastatic disease
in L2-3 spine diagnosed by magnetic resonance imaging scan.
Computed Tomography (CT) scan showed multiple metastases
of different sizes in both lungs, a metastatic nodule in thyroid,
and a mass in the posterior chest wall measuring 2.0 cc with
maximum dimensions 1.8x1.7x1.2 cm. Single-Photon Emission
Computed Tomography (SPECT) scan also showed multiple
metastases in right parietal bone, cervical vertebra, L2-3 spine,
left ilium, and right sacroiliac joint.
The patient was found to have EGFR exon 20 insertion
mutation, ALK and ROS-1 negative and over 70% expression
of PD-L1. The patient started the first cycle of checkpoint
inhibitor therapy using Pembrolizumab, an anti-PD-1
monoclonal antibody (100mg ivgtt d1 q3w) on September
30th, 2017. While the treatment was on going, the metastatic
Jiang et al. Case Report: Lattice Radiation Therapy With Immunotherapy
Frontiers in Oncology | www.frontiersin.org February 2021 | Volume 10 | Article 5481322
mass in the posterior chest wall grew rapidly from 2.0 cc to 63.2
cc with maximum dimensions 5.0 × 5.4 × 5.3 cm on October 10,
2017, in less than a month, (Figures 1A, D). The lesion was
ulcerated with slight local bleeding. New metastases in brain and




The decision was to treat the fast-growing posterior chest wall
mass with HDLRT to combine with the on-going anti-PD-
1 treatment.
Treatment planning was performed on the MULTIPLAN
(Accuray, Incorporated, Sunnyvale, CA). A CyberKnife VSI
Robotic Radiosurgery System (Accuray, Incorporated,
Sunnyvale, CA) was used for delivering a single fraction of
LRT with 20 Gy prescribed to six high-dose vertices.
The HDLRT was configured with six spherical high dose
vertices with diameter of 1.0 cm distributed within the GTV and
with 2.0 cm of separation (center to center). The optimized plan
resulted in the doses covering 98%, 95%, 50%, and 5% of the
vertices volume (D98, D95, D50, and D5%) being 20.95, 21.40,
24.88, and 27.85 Gy, respectively; the maximal dose of the spinal
cord and rib being 2.67 and 7.45 Gy, respectively. The dose
distribution is shown in Figure 2. The dose-volume histograms
(DVHs) of the high-dose vertices, GTV, ribs, and spinal cord
were shown in Figure 3. The Peak-to-Valley dose profile (Figure
4) showed the valley dose between vertices to be about 25% of the
peak dose. Note that only 6.5% of the GTV received the
prescribed vertex dose of 20 Gy and higher, and that the DVH
of the GTV is closely similar to that of the published data
with GRID.
The HDLRT was given on October 18, 2017, 18 days after the
initiation of the first cycle of Pembrolizumab.
Other Treatments
Subsequent to the HDLRT, from October 30, 2017, to March 28,
2018, patient continued to receive another six cycles of
Pembrolizumab (100 mg ivgtt d1 q3w, for each cycle).
Additionally, the patient received SBRT with 10 Gy in two
fractions, 20 Gy in 1 fraction, and 15 Gy in 1 fraction for a
metastatic tumor at the L2-3 spine, a right lung metastasis near
anterior chest wall, and a tumor at the T10 spine, respectively;
CRT with 8 Gy in two fractions and 20 Gy in five fractions for a
spinal metastatic tumor at the C3-5 levels and the whole brain,
respectively; IMRT with 30 Gy in 10 fractions for a thyroid and a
posterior sternal metastasis, and 8 Gy in four fractions for the
metastatic abdominal lymph nodes, respectively; LRT with 12
and 10 Gy in 1 fraction for the spinal metastatic tumors at the L3
spine and psoas, and the metastatic abdominal lymph nodes,
respectively. From February 2018 to May 2018, the patient also
received four cycles of VEGF targeted therapies with
bevacizumab and three cycles of chemotherapy with
gemcitabine. The timeline and therapeutic interventions were
listed in Supplementary Table 1.
Clinical Outcome
While all metastatic lesions responded to various palliative
treatments, only the posterior chest wall metastatic tumor
achieved complete response. Under the background of anti-
A B C
D E F
FIGURE 1 | Tumor response to treatment. The metastatic mass in the posterior chest wall, before (A, D) and after (B, C, E, F) HDLRT on October 18th.
(Permission by Radiation Research to extract from Figure 3 in Wu X et al. (10). © 2021 Radiation Research Society).
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PD1 treatment, the tumor regressed 77.84% over one month
after the HDLRT and then continued to shrink. Two months
after the HDLRT, in addition to further shrinkage, all
symptoms were relieved with the bleeding/discharging totally
under control. This posterior chest wall tumor achieved
complete local response (based on visual and radiographic
exams) five months after the HDLRT without side effects
(Figures 1B, C, E, F).
A B
C D
FIGURE 2 | The LATTICE dose distribution in a 3D view (A); in an axial plane (B); in a sagittal plane (C); and in a coronal plane (D). The high-dose vertices (total of
six) received 20 Gy to the 69% isodose line. The doses between the dose-vertices (valley) were in the order of 25% of the maximum (peak) dose. (Permission by
Radiation Research to extract from Figure 3 in Wu X et al. (10). © 2021 Radiation Research Society).
FIGURE 3 | The dose-volume histograms (DVHs) of high dose-vertices, GTV, and normal tissue. D99.3% of the vertices was 20 Gy. The doses to the ribs and
spinal cord were effectively minimized.
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CT scans of the chest and abdomen on May 10, 2018 showed
progression of multiple metastases in both lungs, mediastinum,
retroperitoneum, right lower pleura, left upper middle abdominal
cavity, double ilium, uterus, and T10 spine. Metastases in the right
thyroid, pancreatic neck, bilateral adrenal glands, both kidneys, L3
spine and psoas, and C3-C5 spine were stable. Metastases in the
right sternoclavicular joint and right lung near anterior chest wall
shrank moderately. Due to the subsequent progression of
metastases in multiple sites with cancerous fever and abdominal
infection, the patient finally succumbed to the disease, seven
months after the HDLRT. The treatment site of the posterior
chest wall remained disease-free until patient’s death.
DISCUSSION
Radiation therapy when used for palliative management of
advanced cancers employs either conventional fractionation or
SBRT regimens with dose lower than that of definitive, curative
treatments, and would expectedly result in partial tumor
response. LRT when used as palliative treatment would also
lead to partial response in general. LRT as a safe boost to
conventionally fractionated radiotherapy had shown clinical
success in a variety of bulky tumors such as advanced
gynaecological tumors and voluminous lung tumors (11–15).
The first patient with locally advanced lung cancer treated with
LRT followed by conventionally fractionated radiotherapy,
combined with chemotherapy demonstrated excellent clinical
response after 6 years follow-up (13). Since 2010, over 150
patients have been treated with LRT and more reports of
clincal outcomes are anticipated (10). However, to this day,
LRT alone as induction of anti-tumor T-cell immunity, to
combine with immune checkpoint blockade treatment has not
been reported.
In the reported case, with the anti-PD1 treatment in parallel,
except for the posterior chest wall lesion that received HDLRT of
20 Gy, all other lesions achieved only partial response, including
the ones treated with SBRT of 20 Gy in a single fraction (full
tumor coverage), and LRTs with 10 Gy and 12 Gy of vertex
doses. This implies that not only a high dose (20 Gy or higher) is
essential; the spatial fractionation with Peak-Valley or High-Low
dose alternation within the tumor volume might also be critical
to mediate effective anti-tumor immune response. This is
consistent with a number of research works favoring high dose
for effective anti-tumor T-cell priming (20, 21, 25, 30), and that
when combined with low-dose treatment, radiation-induced
immune modulation might be augmented (38, 39).
Additionally, it has been postulated that the low dose regions
(valleys) might preserve the perfusion needed for circulating the
factors essential for anti-tumor immunity (10, 40–44).
It is worth noting that, with only 6.5% of the GTV receiving
the dose of 20 Gy and higher, the effective uniform dose (EUD)
of the GTV was calculated to be 1.2 Gy, using Niemierko’s
phenomenological model (45) with a=−10 (typically suggested
for tumors). Based on the traditionally understood mechanism of
radiobiology, the probability of achieving complete local control
with such a dose for a tumor of 63 cc would be nearly zero. Given
the fact that this tumor was not responsive to the initial anti-PD1
treatment and none of the other tumors showed significant
reduction throughout the curse of the treatments, the
synergetic effect of combining HDLRT with anti-PD1 becomes
a plausible speculation. To summarize the postulated
mechanism, in HDLRT the dose in the vertices are sufficiently
high (>20 Gy) to induce neo-antigen release and initiate the
cascade of APC (antigen presenting cell)-based T-cell priming;
the dose in between the vertices is low enough to preserve
internal tumor circulation/perfusion to potentially facilitate the
infiltration of APCs and the primed cytotoxic T-cells; the highly
heterogeneous dose configuration could reprogram the
immunosuppressive TME to become more immunogenic; and
when synergistically treated by checkpoint inhibitors, the primed
T cells could attack tumor cells without being exhausted.
A B
FIGURE 4 | (A) Dose distribution in a coronal plane. The peak-valley dose profile (B) along the green line marked in panel (A), showing the peak to valley dose ratio
of about 4. (Permission by Radiation Research to extract from Figure 3 in Wu X et al. (10). © 2021 Radiation Research Society).
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Mohiuddin et al. treated a pembrolizumab-refractory patient
with locally advanced melanoma who was dramatically re-
sensitised to the same drug by the administration of parallel
opposed, spatially fractionated GRID radiation therapy. Their
result suggested the similar synergistic effect of high-dose GRID
radiation therapy as a primer for immunological response (46).
Our finding echoes with their result. However, abscopal response
of other tumors with the appreciable magnitude was not
observed in this case study.
CONCLUSION
SFRT, with its long history of evolution is currently gaining new
momentum and much of the new potentials are awaited for
further exploration (47). LRT can safely deliver potentially
immunogenic high dose to partial volume of bulky tumors.
When combined with immune checkpoint blockades,
therapeutic effects greater than traditional palliation/de-
bulking, and even complete local tumor eradication are
possible. The reported case showed the dramatic difference in
tumor response between HDLRT and an array of palliative
radiation therapy regimens when combined with anti-PD1
immunotherapy in a same individual, suggesting such strategy
of combining HDLRT and immune checkpoint blockades might
present a universally applicable treatment option if the clinical
efficacy and safety can be systemically tested and proven.
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